Literature DB >> 15604872

Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models.

Eric G Romanowski1, Patricia Pless, Kathleen A Yates, Y Jerold Gordon.   

Abstract

PURPOSE: To determine the effects of topical cyclosporine A (CsA), an immunomodulating T-cell inhibitor, on the formation of subepithelial immune corneal infiltrates (SEIs) and acute adenovirus replication in the NZW Rabbit Ad5 SEI and Ad5 replication models.
METHODS: In the Ad5 SEI model, eyes were treated topically with either 2% CsA in corn oil, 0.5% CsA in artificial tears, or their respective control vehicles 4 times daily for 14 days and then twice daily for 4 days. SEIs were graded on day 23 by masked slit-lamp examination. Using the same treatment protocol in the Ad5 replication model, rabbit eyes were cultured on days 0, 1, 3, 4, 5, 7, 9, 11, 14, 16, 18, and 21 postinoculation, and their tear film viral titers were determined on A549 cells.
RESULTS: The formation of SEIs was significantly reduced following treatment with either 2.0% or 0.5% CsA. However, 2% and 0.5% CsA significantly increased viral titers on several days, prolonged the duration of Ad5 shedding, and increased the number of Ad5-positive cultures per total during the late phase of infection (days 7-21) compared with their respective controls. The 0.5% CsA was equipotent to 2% CsA for most outcome parameters tested.
CONCLUSIONS: A role for topical CsA in the treatment of adenovirus ocular infections remains to be defined in large, randomized controlled clinical trials. During acute infection, reducing SEI formation is highly desirable, but enhancing viral replication may inadvertently serve to promote local epidemics. Future trials should address the important issues of optimized formulation and dose regimen and the possibility of prolonging virus shedding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15604872     DOI: 10.1097/01.ico.0000127481.23714.b6

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  10 in total

1.  Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.

Authors:  L Asena; E Şıngar Özdemir; A Burcu; E Ercan; M Çolak; D D Altınörs
Journal:  Eye (Lond)       Date:  2017-02-03       Impact factor: 3.775

2.  Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.

Authors:  Eliya Levinger; Omer Trivizki; Yonathan Shachar; Samuel Levinger; David Verssano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-04       Impact factor: 3.117

3.  Development of EKC after eximer laser photorefractive surgery and subsequent recurrence of EKC-like keratitis.

Authors:  Sung Joon Park; Yoon Soo Jang; Tae Hyuk Koh; Young A Kwon; Sang Wroul Song
Journal:  Korean J Ophthalmol       Date:  2011-11-22

4.  Evaluation of knowledge, attitude, and behaviour of ophthalmologists about adenoviral conjunctivitis transmission and treatment : An online survey for Turkish ophthalmologists.

Authors:  Gozde Sahin Vural; Ozlem Barut Selver; Melis Palamar
Journal:  Int Ophthalmol       Date:  2022-05-11       Impact factor: 2.029

5.  [Cyclosporin A eyedrops for keratitis nummularis after adenovirus keratoconjunctivitis].

Authors:  D Böhringer; F Birnbaum; T Reinhard
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

6.  Ganciclovir ophthalmic gel treatment shortens the recovery time and prevents complications in the adenoviral eye infection.

Authors:  Serkan Ozen; Murat A Ozer
Journal:  Int Ophthalmol       Date:  2016-05-24       Impact factor: 2.031

Review 7.  Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis.

Authors:  Rahul A Jonas; Lawson Ung; Jaya Rajaiya; James Chodosh
Journal:  Prog Retin Eye Res       Date:  2019-12-28       Impact factor: 21.198

8.  A 8-year retrospective clinical analysis of 272 patients of epidemic Keratoconjunctivitis in Beijing, China.

Authors:  Wenbo Hou; Xuguang Sun; Jun Feng; Yang Zhang; Zhiqun Wang
Journal:  BMC Ophthalmol       Date:  2019-12-19       Impact factor: 2.209

9.  Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.

Authors:  Seydi Okumus; Erol Coskun; Mehmet Gurkan Tatar; Erdal Kaydu; Ramazan Yayuspayi; Aysegul Comez; Ibrahim Erbagci; Bulent Gurler
Journal:  BMC Ophthalmol       Date:  2012-08-18       Impact factor: 2.209

Review 10.  Disparate Entry of Adenoviruses Dictates Differential Innate Immune Responses on the Ocular Surface.

Authors:  Matthew R Pennington; Amrita Saha; David F Painter; Christina Gavazzi; Ashrafali M Ismail; Xiaohong Zhou; James Chodosh; Jaya Rajaiya
Journal:  Microorganisms       Date:  2019-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.